576.98
price up icon1.60%   9.09
after-market Handel nachbörslich: 575.10 -1.88 -0.33%
loading
Schlusskurs vom Vortag:
$567.89
Offen:
$567.89
24-Stunden-Volumen:
769.29K
Relative Volume:
0.79
Marktkapitalisierung:
$60.10B
Einnahmen:
$14.21B
Nettoeinkommen (Verlust:
$4.46B
KGV:
14.54
EPS:
39.68
Netto-Cashflow:
$3.56B
1W Leistung:
-1.46%
1M Leistung:
-2.12%
6M Leistung:
-12.71%
1J Leistung:
-44.84%
1-Tages-Spanne:
Value
$566.00
$577.98
1-Wochen-Bereich:
Value
$565.45
$603.47
52-Wochen-Spanne:
Value
$476.49
$1,070.00

Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile

Name
Firmenname
Regeneron Pharmaceuticals Inc
Name
Telefon
(914) 847-7000
Name
Adresse
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Name
Mitarbeiter
15,207
Name
Twitter
@regeneron
Name
Nächster Verdiensttermin
2025-08-01
Name
Neueste SEC-Einreichungen
Name
REGN's Discussions on Twitter

Vergleichen Sie REGN mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
576.98 60.19B 14.21B 4.46B 3.56B 39.68
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
376.62 97.36B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
458.37 59.56B 2.46B -319.09M -52.09M -2.47
Biotechnology icon
ARGX
Argen X Se Adr
729.76 44.94B 3.06B 1.28B 447.35M 21.30
Biotechnology icon
ONC
Beone Medicines Ltd Adr
329.84 36.14B 3.81B -644.79M -669.77M -6.24

Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-08-14 Eingeleitet Rothschild & Co Redburn Buy
2025-06-30 Herabstufung Argus Buy → Hold
2025-05-30 Herabstufung RBC Capital Mkts Outperform → Sector Perform
2025-05-30 Herabstufung Wells Fargo Overweight → Equal Weight
2025-05-14 Hochstufung Citigroup Neutral → Buy
2025-04-22 Fortgesetzt Cantor Fitzgerald Overweight
2025-02-05 Hochstufung Leerink Partners Market Perform → Outperform
2025-01-16 Herabstufung UBS Buy → Neutral
2024-12-10 Fortgesetzt BofA Securities Underperform
2024-11-15 Eingeleitet Wolfe Research Outperform
2024-11-14 Eingeleitet Citigroup Neutral
2024-09-24 Herabstufung Leerink Partners Outperform → Market Perform
2024-03-12 Eingeleitet Bernstein Outperform
2024-01-12 Hochstufung RBC Capital Mkts Sector Perform → Outperform
2023-11-09 Eingeleitet Deutsche Bank Hold
2023-11-03 Hochstufung Raymond James Mkt Perform → Outperform
2023-08-21 Hochstufung Canaccord Genuity Hold → Buy
2023-08-21 Bestätigt Oppenheimer Perform
2023-06-28 Herabstufung Canaccord Genuity Buy → Hold
2023-03-27 Hochstufung SVB Securities Market Perform → Outperform
2023-03-24 Hochstufung Jefferies Hold → Buy
2023-03-23 Hochstufung Raymond James Underperform → Mkt Perform
2023-01-30 Hochstufung Cowen Market Perform → Outperform
2023-01-20 Hochstufung JP Morgan Neutral → Overweight
2022-10-26 Herabstufung Raymond James Mkt Perform → Underperform
2022-10-17 Herabstufung Evercore ISI Outperform → In-line
2022-09-09 Hochstufung Jefferies Underperform → Hold
2022-09-09 Hochstufung Morgan Stanley Equal-Weight → Overweight
2022-07-25 Herabstufung SVB Leerink Outperform → Mkt Perform
2022-07-13 Eingeleitet Cantor Fitzgerald Neutral
2022-06-06 Eingeleitet Jefferies Underperform
2022-05-23 Eingeleitet SVB Leerink Outperform
2022-01-05 Herabstufung BofA Securities Neutral → Underperform
2022-01-03 Hochstufung Bernstein Mkt Perform → Outperform
2021-12-15 Herabstufung Bernstein Outperform → Mkt Perform
2021-12-09 Fortgesetzt Wells Fargo Overweight
2021-12-07 Fortgesetzt Cowen Market Perform
2021-12-06 Eingeleitet Goldman Buy
2021-11-19 Fortgesetzt BMO Capital Markets Outperform
2021-11-05 Herabstufung The Benchmark Company Buy → Hold
2021-06-29 Eingeleitet H.C. Wainwright Buy
2021-01-25 Hochstufung BMO Capital Markets Market Perform → Outperform
2021-01-13 Hochstufung The Benchmark Company Hold → Buy
2021-01-08 Hochstufung Citigroup Neutral → Buy
2020-10-05 Hochstufung Cantor Fitzgerald Neutral → Overweight
2020-08-20 Herabstufung The Benchmark Company Buy → Hold
2020-07-09 Hochstufung SunTrust Hold → Buy
2020-05-26 Hochstufung Wells Fargo Equal Weight → Overweight
2020-04-28 Herabstufung Citigroup Buy → Neutral
2020-04-17 Hochstufung The Benchmark Company Hold → Buy
2020-04-08 Eingeleitet The Benchmark Company Hold
2020-03-31 Eingeleitet Wolfe Research Peer Perform
2020-02-27 Eingeleitet Barclays Overweight
2020-02-26 Hochstufung Canaccord Genuity Hold → Buy
2020-02-26 Herabstufung Robert W. Baird Outperform → Neutral
2020-02-25 Hochstufung Jefferies Hold → Buy
2020-02-11 Hochstufung Argus Hold → Buy
2019-12-24 Eingeleitet Raymond James Mkt Perform
2019-12-16 Herabstufung Evercore ISI Outperform → In-line
2019-12-13 Hochstufung Credit Suisse Neutral → Outperform
2019-11-12 Eingeleitet SunTrust Hold
2019-11-07 Hochstufung Citigroup Neutral → Buy
2019-10-17 Fortgesetzt BofA/Merrill Neutral
2019-09-23 Hochstufung Guggenheim Neutral → Buy
Alle ansehen

Regeneron Pharmaceuticals Inc Aktie (REGN) Neueste Nachrichten

pulisher
04:26 AM

JPMorgan Calls the Selloff Excessive, Trims Regeneron Pharmaceuticals, Inc. (REGN) Price Target - MSN

04:26 AM
pulisher
02:43 AM

Regeneron at Bernstein Forum: Strategic Growth & Challenges By Investing.com - Investing.com Canada

02:43 AM
pulisher
04:56 AM

Diversified Trust Co Acquires 1,015 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

04:56 AM
pulisher
04:40 AM

Golden State Equity Partners Has $459,000 Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

04:40 AM
pulisher
01:57 AM

Regeneron’s Phase 2 COURAGE Trial Shows Trevogrumab Combination Preserves Lean Mass in Obesity Patients on Semaglutide - Yahoo Finance

01:57 AM
pulisher
Sep 23, 2025

Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Sumitomo Mitsui DS Asset Management Company Ltd - MarketBeat

Sep 23, 2025
pulisher
Sep 23, 2025

Livforsakringsbolaget Skandia Omsesidigt Sells 10,460 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

Sep 23, 2025
pulisher
Sep 23, 2025

Procyon Advisors LLC Sells 5,942 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

Sep 23, 2025
pulisher
Sep 23, 2025

Biotech Stocks Facing FDA Decision In October 2025 - RTTNews

Sep 23, 2025
pulisher
Sep 23, 2025

Regeneron Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors - MSN

Sep 23, 2025
pulisher
Sep 23, 2025

Regeneron: Looking For Green Shoots Of Growth On Top Of Heartwood Franchises - Seeking Alpha

Sep 23, 2025
pulisher
Sep 23, 2025

Avanza Fonder AB Raises Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

Sep 23, 2025
pulisher
Sep 23, 2025

Why Regeneron (REGN) Stock Is Down Today - Yahoo Finance

Sep 23, 2025
pulisher
Sep 23, 2025

Regeneron Pharmaceuticals (NASDAQ:REGN) Shares Gap DownHere's Why - MarketBeat

Sep 23, 2025
pulisher
Sep 23, 2025

Should European Dupixent Approval Recommendation Prompt Regeneron (REGN) Investors to Reevaluate Growth Potential? - simplywall.st

Sep 23, 2025
pulisher
Sep 23, 2025

US FDA declines to approve Scholar Rock's muscle weakness drug; shares fall - Reuters

Sep 23, 2025
pulisher
Sep 23, 2025

Eaton Financial Holdings Company LLC Takes $494,000 Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

Sep 23, 2025
pulisher
Sep 23, 2025

Assenagon Asset Management S.A. Sells 58,064 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

Sep 23, 2025
pulisher
Sep 22, 2025

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Receives $817.67 Consensus Target Price from Analysts - MarketBeat

Sep 22, 2025
pulisher
Sep 22, 2025

Kingstone Capital Partners Texas LLC Invests $40.74 Million in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

Sep 22, 2025
pulisher
Sep 22, 2025

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Sees Significant Growth in Short Interest - MarketBeat

Sep 22, 2025
pulisher
Sep 22, 2025

Thalassemia Treatment Market to Witness Significant Growth by 2034 Driven by Novel Drug Development | DelveInsight - GlobeNewswire Inc.

Sep 22, 2025
pulisher
Sep 22, 2025

SNY & REGN's Dupixent Receives CHMP Backing for Urticaria in EU - Yahoo Finance

Sep 22, 2025
pulisher
Sep 22, 2025

All Eyes on ELYEA–Sandoz Defeats Preliminary Injunction - The National Law Review

Sep 22, 2025
pulisher
Sep 22, 2025

Founders Capital Management LLC Purchases 538 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

Sep 22, 2025
pulisher
Sep 22, 2025

Regeneron Pharmaceuticals, Inc. $REGN Shares Bought by Clear Harbor Asset Management LLC - MarketBeat

Sep 22, 2025
pulisher
Sep 22, 2025

Sanofi (SNY) Advances with Dupixent for Skin Condition in EU - GuruFocus

Sep 22, 2025
pulisher
Sep 22, 2025

Alvotech Files PGR Against Regeneron High-Dose Aflibercept Patent - MarketScreener

Sep 22, 2025
pulisher
Sep 22, 2025

Exchange Traded Concepts LLC Buys 588 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

Sep 22, 2025
pulisher
Sep 22, 2025

Sovran Advisors LLC Invests $2.75 Million in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

Sep 22, 2025
pulisher
Sep 22, 2025

Sanofi, Regeneron's Chronic Spontaneous Urticaria Drug Lands Positive Recommendation in Europe - MarketScreener

Sep 22, 2025
pulisher
Sep 22, 2025

Czech National Bank Grows Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

Sep 22, 2025
pulisher
Sep 22, 2025

Regeneron and Sanofi Announce Positive CHMP Opinion for Dupixent® in Treating Chronic Spontaneous Urticaria in the European Union - Quiver Quantitative

Sep 22, 2025
pulisher
Sep 22, 2025

Dupixent® (dupilumab) to Treat Chronic Spontaneous Urticaria (CSU) Advances in EU with Positive CHMP Opinion - The Manila Times

Sep 22, 2025
pulisher
Sep 22, 2025

Press Release: Sanofi and Regeneron’s Dupixent to treat chronic spontaneous urticaria advances in EU with positive CHMP opinion - The Manila Times

Sep 22, 2025
pulisher
Sep 22, 2025

Regeneron Pharmaceuticals Inc says Dupixent (dupilumab) to treat chronic spontaneous urticaria (csu) advances in EU with positive CHMP opinion - MarketScreener

Sep 22, 2025
pulisher
Sep 21, 2025

Bond Watch: Why is Regeneron Pharmaceuticals Inc stock going downPortfolio Performance Report & Technical Pattern Based Buy Signals - خودرو بانک

Sep 21, 2025
pulisher
Sep 21, 2025

Regeneron Pharmaceuticals, Inc. (REGN): A Bull Case Theory - MSN

Sep 21, 2025
pulisher
Sep 20, 2025

How the Narrative for Regeneron Has Shifted with Pipeline Wins and Analyst Optimism - Yahoo Finance

Sep 20, 2025
pulisher
Sep 20, 2025

Woodstock Corp Purchases 906 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

Sep 20, 2025
pulisher
Sep 19, 2025

What are the future prospects of Regeneron Pharmaceuticals IncGlobal Markets & Entry Point Strategy Guides - خودرو بانک

Sep 19, 2025
pulisher
Sep 19, 2025

Signal Recap: What are the future prospects of Regeneron Pharmaceuticals IncJuly 2025 Sector Moves & Safe Capital Growth Tips - خودرو بانک

Sep 19, 2025
pulisher
Sep 19, 2025

Regeneron To Pit Lynozyfic Against J&J’s Darzalex In Smoldering Myeloma - insights.citeline.com

Sep 19, 2025
pulisher
Sep 19, 2025

Regeneron Pharmaceuticals, Inc. $REGN Holdings Decreased by Harbor Investment Advisory LLC - MarketBeat

Sep 19, 2025
pulisher
Sep 19, 2025

Applying chart zones and confluence areas to Regeneron Pharmaceuticals Inc.Portfolio Return Report & High Accuracy Swing Entry Alerts - newser.com

Sep 19, 2025
pulisher
Sep 19, 2025

Market Pulse: Whats the RSI of General Motors Company stock2025 Support & Resistance & Safe Capital Investment Plans - khodrobank.com

Sep 19, 2025
pulisher
Sep 19, 2025

Regeneron says blood cancer therapy shows 100% response rate in precancerous disorder study - Reuters

Sep 19, 2025
pulisher
Sep 19, 2025

Regeneron’s Lynozyfic yields 100% response rate in small smoldering multiple myeloma study - Endpoints News

Sep 19, 2025

Finanzdaten der Regeneron Pharmaceuticals Inc-Aktie (REGN)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$458.37
price up icon 0.87%
$729.76
price down icon 0.63%
biotechnology ONC
$329.84
price up icon 0.23%
$141.00
price down icon 3.01%
$99.75
price up icon 1.51%
Kapitalisierung:     |  Volumen (24h):